The new year has been tough on pharmaceutical stocks, including JNJ. But it should not be read as an indictment on the company's operations.
Original news source Credit: www.cnbc.com
Johnson & Johnson deserves more credit for another healthy quarter and strong guidance added by News89 Team on
View all posts by News89 Team →
You must be logged in to post a comment Login